| 4.07 -0.125 (-2.98%) | 03-13 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.57 |
1-year : | 6.26 |
| Resists | First : | 4.77 |
Second : | 5.36 |
| Pivot price | 4.71 |
|||
| Supports | First : | 3.81 | Second : | 3.17 |
| MAs | MA(5) : | 4.46 |
MA(20) : | 4.67 |
| MA(100) : | 3.4  |
MA(250) : | 2.57 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 26.8 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 9.07 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ THAR ] has closed below the lower bollinger band by 7.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ THAR ] is to continue within current trading range. Bollinger Bands are 14.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.42 | 4.42 - 4.45 |
| Low: | 3.95 - 3.98 | 3.98 - 4.01 |
| Close: | 4.02 - 4.07 | 4.07 - 4.12 |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Tue, 17 Feb 2026
Tharimmune rebrands as Canton Strategic Holdings with new ticker CNTN - Investing.com
Fri, 23 Jan 2026
Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization - Seeking Alpha
Thu, 22 Jan 2026
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering - Yahoo Finance
Thu, 22 Jan 2026
Biotech and blockchain player Tharimmune raises $55M for Canton strategy - Stock Titan
Tue, 20 Jan 2026
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering - Yahoo Finance
Fri, 21 Nov 2025
Tharimmune Stock Plummets -46% With 9-Day Losing Streak - Trefis
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 22.6 (%) |
| Held by Institutions | 22.2 (%) |
| Shares Short | 2,580 (K) |
| Shares Short P.Month | 1,420 (K) |
| EPS | -3.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -99.8 % |
| Return on Equity (ttm) | -225.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 0 |
| Price to Book value | 4.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|